XDx and LabCorp Enter Into Expanded North American Agreement for XDx's AlloMap

XDx, Inc today announced that it has entered into a multi-year agreement with Laboratory Corporation of America Holdings LH to provide heart transplant patients eligible for XDx's AlloMap test with the convenience of having their blood drawn at participating LabCorp sites across the United States. Under the terms of the agreement, LabCorp will be XDx's preferred third-party non-hospital provider for phlebotomy and specimen processing for all XDx AlloMap molecular expression tests conducted in North America. This expanded agreement follows a successful one-year pilot between the companies at select LabCorp blood draw sites. The XDx reference lab will also continue to perform the proprietary AlloMap test.